Combination of Anlotinib and Temozolomide Results in Sustained Response in Multimodal-Resistant Primary Breast Angiosarcoma with Metastasis to Skull Base and Dural Involvement: A Case Study - Takeaways - MDSpire

Combination of Anlotinib and Temozolomide Results in Sustained Response in Multimodal-Resistant Primary Breast Angiosarcoma with Metastasis to Skull Base and Dural Involvement: A Case Study

  • By

  • Shujie Song

  • Weiyi Chen

  • Xixi Li

  • Yongxia Zhang

  • Yanchun Wang

  • April 27, 2026

  • 0 min

Share

  • 1

    Primary breast angiosarcoma is a rare malignancy with a high risk of hematogenous metastasis, including to the skull base and dura.

  • 2

    A 52-year-old woman with stage IIA breast angiosarcoma developed skull base metastasis after multimodal therapy failure.

  • 3

    The combination of anlotinib and temozolomide resulted in rapid symptomatic relief and stable disease in the patient.

  • 4

    This case represents the first documented instance of skull base metastasis and dural involvement from primary breast angiosarcoma.

  • 5

    The findings suggest that targeting angiogenesis and using CNS-penetrating agents may be effective for treating refractory angiosarcoma.

Original Source(s)

Combination of Anlotinib and Temozolomide Results in Sustained Response in Multimodal-Resistant Primary Breast Angiosarcoma with Metastasis to Skull Base and Dural Involvement: A Case Study

  • by Shujie Song, Weiyi Chen, Xixi Li, Yongxia Zhang, Yanchun Wang

  • April 27, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer